Immunocan

Shanghai Immunocan Biotech Co., Ltd. is a biopharmaceutical company that possesses internationally cutting-edge gene editing technology. With a core focus on the self-developed fully humanized antibody animal platform, the company is dedicated to innovative antibody drug research and development. The company is jointly formed by top scientists from China's leading research institution, the Chinese Academy of Sciences, and professionals from the world's top cancer research institute, the MD Anderson Cancer Center in the United States. Its gene editing technology, model animal development, tumor immunotherapy, and multi-omics comprehensive analysis are at the forefront globally and hold a leading position in China. Additionally, the company has established a fully humanized animal platform to assist pharmaceutical companies in developing immune antibody drugs by using gene editing technology to perform gene replacement in multiple species. This serves as an integrated R&D platform combining biotechnology and gene screening.